NVS Apr 2023 110.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:58PM EST
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 110.00 |
| Expiry date | 2023-04-21 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 225 |
- Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
- Zacks
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
- GlobeNewswire
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar)
© 2023 Yahoo. All rights reserved.
